Key terms
About MIRM
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest MIRM news
Apr 16
4:35pm ET
Buy Rating Affirmed for Mirum Pharmaceuticals Amidst Strategic Positioning and Treatment Breakthroughs
Apr 16
4:20pm ET
Mirum Pharmaceuticals initiated with a Buy at Stifel
Apr 16
6:05am ET
Buy Rating Affirmed for Mirum Pharmaceuticals Amid Positive Clinical Trial Outlook
Apr 05
1:25pm ET
Mirum Pharmaceuticals participates in a conference call with JPMorgan
Apr 05
4:55am ET
Mirum Pharmaceuticals participates in a conference call with JPMorgan
Apr 04
4:35pm ET
Mirum Pharmaceuticals participates in a conference call with JPMorgan
Apr 02
11:50am ET
Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM) and Rocket Pharmaceuticals (RCKT)
Mar 18
8:25am ET
Mirum Pharmaceuticals price target lowered to $43 from $44 at Leerink
Mar 17
2:02am ET
Mirum Pharmaceuticals’ Financial Uncertainty: FDA Approval Hurdles for Chenodal’s CTX Treatment
Mar 14
6:25am ET
Mirum Pharmaceuticals’ LIVMARLI: A Strong Buy on Expanded FDA Approval and Promising Commercial Outlook
Mar 14
3:29am ET
3 Best Stocks to Buy Now, 3/14/2024, According to Top Analysts
Mar 14
12:25am ET
Buy Rating Affirmed for Mirum Pharmaceuticals Following FDA Approval and Positive Revenue Outlook
Mar 13
6:00pm ET
Mirum Pharmaceuticals’ Livmarli receives FDA approval
Mar 01
10:50am ET
Cantor Fitzgerald biotech analyst holds an analyst/industry conference call
Mar 01
10:07am ET
Cantor Fitzgerald biotech analyst holds an analyst/industry conference call
Mar 01
1:16am ET
Buy Rating Affirmed for Mirum Pharmaceuticals Amid Strong Q4 Performance and Optimistic 2024 Outlook
Mar 01
1:10am ET
Buy Rating Affirmed for Mirum Pharmaceuticals Amid Strong Financials and Promising Regulatory Milestones
Feb 29
11:21am ET
Mirum Pharmaceuticals price target lowered to $45 from $58 at H.C. Wainwright
Feb 29
8:47am ET
Mirum Pharmaceuticals publishes data from Livmarli analysis
Feb 29
7:20am ET
Mirum Pharmaceuticals price target raised to $69 from $64 at JMP Securities
Feb 29
12:40am ET
Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM) and Integra Lifesciences (IART)
Feb 28
4:14pm ET
Mirum Pharmaceuticals reports Q4 revenue $69.554M, consensus $67.91M
Feb 27
6:26am ET
Buy Rating Affirmed for Mirum Pharmaceuticals on Strong Sales and Growth Prospects
Feb 25
11:26pm ET
Mirum Pharmaceuticals’ Strategic Acquisition Spurs Positive Market Projection and Maintains Buy Rating
Jan 31
6:55am ET
Mirum Pharmaceuticals management to meet with Cantor Fitzgerald
Jan 30
5:55am ET
Mirum Pharmaceuticals management to meet with Cantor Fitzgerald
Jan 25
6:43am ET
Mirum Pharmaceuticals management to meet with Cantor Fitzgerald
MIRM Financials
Key terms
Ad Feedback
MIRM Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
MIRM Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
